

# Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With ACS: TICO Trial

**OBJECTIVE:** Whether switching to ticagrelor monotherapy after 3 months of DAPT reduces net adverse clinical events compared with ticagrelor-based 12-month DAPT in patients with ACS treated with drug-eluting stents.



3056 patients



Randomized multicenter trial, between 2015-2018, 38 centers in South Korea

Ticagrelor monotherapy (90mg twice daily) after 3-month DAPT  
(n = 1527)


Ticagrelor-based 12-month DAPT  
(n = 1529)



Among patients with ACS treated with new-generation drug-eluting stents, use of **Ticagrelor monotherapy after 3 months of DAPT** resulted in a modest but statistically significant reduction in a composite outcome of major bleeding and adverse cardiac and cerebrovascular events at 1 year.



## Primary outcome of the net adverse clinical event



Net adverse clinical event:

Composite of major bleeding and adverse cardiac and cerebrovascular events

Ticagrelor monotherapy **3.9%**

Ticagrelor-based 12-month DAPT **5.9%**